CLEOCIN T (clindamycin phosphate) by Pfizer is mechanism of action the mechanism of action of clindamycin in treating acne vulgaris is unknown. First approved in 1989.
Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
CLEOCIN T (clindamycin phosphate) is a topical lotion antibiotic indicated for acne vulgaris, approved in 1989. The exact mechanism of action in acne treatment remains unknown, though clindamycin is a lincosamide class antibiotic. It represents a mature, well-established dermatology product in the topical acne market.
As a product approaching loss of exclusivity with moderate competitive pressure (30/100), commercial teams should expect declining market share and smaller field footprint over the next 3–5 years.
Mechanism of Action The mechanism of action of clindamycin in treating acne vulgaris is unknown.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris
Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide
A Efficacy and Safety of Duac™Compared With Clindamycin Phosphate Gel in the Treatment of Mild to Moderate Acne Vulgaris
W0265-104: A Single-Center, Evaluator-Blinded, Randomized, Placebo-Controlled, Phase 1 Clinical Trial Evaluating the Photoallergic Potential of Topically Applied Clindamycin Phosphate 1.0% and Tretinoin 0.025% (CT Gel) in Healthy Volunteers
Worked on CLEOCIN T at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
CLEOCIN T offers limited career growth opportunities due to its LOE-approaching status and lack of active clinical pipeline. Professionals assigned to this product should view it as a maintenance-phase role focused on maximizing remaining market share against generic competition rather than driving innovation or expansion.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo